|
First Year of Data Show Promising Survival With Transcatheter Aortic Valve
http://www.tctmd.com/show.aspx?id=90272
The first full year of experience with a transcatheter aortic
valve implantation (TAVI) in over 1,000 patients, many of them
not eligible for surgery, shows survival rates over 80% in
patients treated via the transfemoral route, and over 70% in
patients treated via the transapical route. The registry results
were presented May 25 at EuroPCR 2010.
Martyn Thomas, MD, of Guys and St. Thomas' NHS Foundation Trust
(London, United Kingdom), reported the results of the SOURCE
registry's first cohort, which includes 1,038 patients from 32
European centers treated with the Sapien aortic valve (Edwards,
Irvine, CA) from November 2007 to January 2009. One-year
follow-up was available for 98% of patients.
..."Outcomes at 1 year for cohort 1 of the SOURCE registry show
an improvement compared to historical controls, with survival
for the transfemoral approach now greater than 80%," Dr. Thomas
said. "There has been a marked improvement in the transapical
outcomes with survival now similar to historical transfemoral
controls. In addition, lower-risk transapical patients have the
same 1-year risk as transfemoral patients. Cohort 1 outcomes
provide a benchmark against which future TAVI cohorts may be
measured."...
...William Wijns, MD, PhD, of Cardiovascular Center Aalst
(Aalst, Belgium), and chairman of EuroPCR 2010, agreed that the
results represent an important step forward for the TAVI
technology, but he stressed that clinicians should remain
cautious regarding its use.
"There is improved survival with the use of the device," Dr. Wijns told TCTMD in an interview.
"But whether that improves
patient outcome compared with a patient who would still be
denied any form of treatment beside drugs? I don't think we've
proven that yet."
|
